FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2500304834> ?p ?o ?g. }

• W2500304834 endingPage "1255" @default.
• W2500304834 startingPage "1245" @default.
• W2500304834 abstract "Vosaroxin is a first-in-class anticancer quinolone derivative that targets topoisomerase II and induces site-selective double-strand breaks in DNA, leading to tumor cell apoptosis. Vosaroxin has chemical and pharmacologic characteristics distinct from other topoisomerase II inhibitors due to its quinolone scaffold. The efficacy and safety of vosaroxin in combination with cytarabine were evaluated in patients with relapsed/refractory acute myeloid leukemia (AML) in a phase III, randomized, multicenter, double-blind, placebo-controlled study (VALOR). In this study, the addition of vosaroxin produced a 1.4-month improvement in median overall survival (OS; 7.5 months with vosaroxin/cytarabine vs. 6.1 months with placebo/cytarabine; hazard ratio [HR] 0.87, 95 % confidence interval [CI] 0.73-1.02; unstratified log-rank p [Formula: see text] 0.061; stratified log-rank p [Formula: see text]0.024), with the greatest OS benefit observed in patients ≥60 years of age (7.1 vs. 5.0 months; HR 0.75, 95 % CI 0.62-0.92; p [Formula: see text]0.003) and patients with early relapse (6.7 vs. 5.2 months; HR 0.77, 95 % CI 0.59-1.00; p [Formula: see text] 0.039), two AML patient groups that typically have poor prognosis. Here we review the chemical and pharmacologic properties of vosaroxin, how these properties are distinct from those of currently available topoisomerase II inhibitors, how they may contribute to the efficacy and safety profile observed in the VALOR trial, and the status of clinical development of vosaroxin for treatment of AML." @default.
• W2500304834 created "2016-08-23" @default.
• W2500304834 creator A5037307995 @default.
• W2500304834 creator A5043240739 @default.
• W2500304834 creator A5050940843 @default.
• W2500304834 creator A5057545251 @default.
• W2500304834 date "2016-08-02" @default.
• W2500304834 modified "2023-10-14" @default.
• W2500304834 title "Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia" @default.
• W2500304834 cites W140845169 @default.
• W2500304834 cites W1587615774 @default.
• W2500304834 cites W1606320443 @default.
• W2500304834 cites W1965326858 @default.
• W2500304834 cites W1965511397 @default.
• W2500304834 cites W1968926584 @default.
• W2500304834 cites W1972797412 @default.
• W2500304834 cites W1972844288 @default.
• W2500304834 cites W1973339193 @default.
• W2500304834 cites W1976057490 @default.
• W2500304834 cites W1990766453 @default.
• W2500304834 cites W2002689332 @default.
• W2500304834 cites W2006434892 @default.
• W2500304834 cites W2007464877 @default.
• W2500304834 cites W2008907780 @default.
• W2500304834 cites W2010183849 @default.
• W2500304834 cites W2014014132 @default.
• W2500304834 cites W2017908039 @default.
• W2500304834 cites W2020249791 @default.
• W2500304834 cites W2027214692 @default.
• W2500304834 cites W2032441027 @default.
• W2500304834 cites W2045045842 @default.
• W2500304834 cites W2050788953 @default.
• W2500304834 cites W2054641418 @default.
• W2500304834 cites W2059660444 @default.
• W2500304834 cites W2066443781 @default.
• W2500304834 cites W2068449076 @default.
• W2500304834 cites W2068577449 @default.
• W2500304834 cites W2069151403 @default.
• W2500304834 cites W2075320923 @default.
• W2500304834 cites W2075941938 @default.
• W2500304834 cites W2088655914 @default.
• W2500304834 cites W2104590411 @default.
• W2500304834 cites W2106926141 @default.
• W2500304834 cites W2109611268 @default.
• W2500304834 cites W2112885253 @default.
• W2500304834 cites W2117975005 @default.
• W2500304834 cites W2119524520 @default.
• W2500304834 cites W2119525287 @default.
• W2500304834 cites W2122189144 @default.
• W2500304834 cites W2122347701 @default.
• W2500304834 cites W2123597018 @default.
• W2500304834 cites W2124624490 @default.
• W2500304834 cites W2132600317 @default.
• W2500304834 cites W2135763833 @default.
• W2500304834 cites W2161245080 @default.
• W2500304834 cites W2166512951 @default.
• W2500304834 cites W2288488030 @default.
• W2500304834 cites W2312423591 @default.
• W2500304834 cites W2318091958 @default.
• W2500304834 cites W2319438985 @default.
• W2500304834 cites W2915731678 @default.
• W2500304834 cites W369237374 @default.
• W2500304834 cites W4233567369 @default.
• W2500304834 doi "https://doi.org/10.1007/s40265-016-0614-z" @default.
• W2500304834 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4989016" @default.
• W2500304834 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27484675" @default.
• W2500304834 hasPublicationYear "2016" @default.
• W2500304834 type Work @default.
• W2500304834 sameAs 2500304834 @default.
• W2500304834 citedByCount "23" @default.
• W2500304834 countsByYear W25003048342017 @default.
• W2500304834 countsByYear W25003048342018 @default.
• W2500304834 countsByYear W25003048342019 @default.
• W2500304834 countsByYear W25003048342020 @default.
• W2500304834 countsByYear W25003048342021 @default.
• W2500304834 countsByYear W25003048342022 @default.
• W2500304834 countsByYear W25003048342023 @default.
• W2500304834 crossrefType "journal-article" @default.
• W2500304834 hasAuthorship W2500304834A5037307995 @default.
• W2500304834 hasAuthorship W2500304834A5043240739 @default.
• W2500304834 hasAuthorship W2500304834A5050940843 @default.
• W2500304834 hasAuthorship W2500304834A5057545251 @default.
• W2500304834 hasBestOaLocation W25003048341 @default.
• W2500304834 hasConcept C121332964 @default.
• W2500304834 hasConcept C126322002 @default.
• W2500304834 hasConcept C142424586 @default.
• W2500304834 hasConcept C142724271 @default.
• W2500304834 hasConcept C143998085 @default.
• W2500304834 hasConcept C147897179 @default.
• W2500304834 hasConcept C181199279 @default.
• W2500304834 hasConcept C185592680 @default.
• W2500304834 hasConcept C204787440 @default.
• W2500304834 hasConcept C207103383 @default.
• W2500304834 hasConcept C27081682 @default.
• W2500304834 hasConcept C2778041864 @default.
• W2500304834 hasConcept C2778729363 @default.
• W2500304834 hasConcept C2779922871 @default.
• W2500304834 hasConcept C44249647 @default.

• next